Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) fell 2.4% during mid-day trading on Tuesday . The stock traded as low as $100.19 and last traded at $99.85. 69,811 shares were traded during trading, a decline of 92% from the average session volume of 856,247 shares. The stock had previously closed at $102.34.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on BNTX shares. Citigroup started coverage on BioNTech in a report on Thursday, March 13th. They issued a "buy" rating and a $145.00 target price for the company. Truist Financial initiated coverage on shares of BioNTech in a research report on Friday, January 10th. They issued a "buy" rating and a $172.00 price target for the company. HC Wainwright lowered their price objective on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. BMO Capital Markets upped their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Finally, Morgan Stanley dropped their price target on BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, BioNTech currently has a consensus rating of "Moderate Buy" and an average price target of $143.44.
Get Our Latest Stock Analysis on BioNTech
BioNTech Stock Performance
The stock's fifty day simple moving average is $102.79 and its 200-day simple moving average is $111.00. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $23.70 billion, a PE ratio of -47.03 and a beta of 1.07.
BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech's revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.90 earnings per share. On average, research analysts predict that BioNTech SE will post -3.88 earnings per share for the current fiscal year.
Institutional Investors Weigh In On BioNTech
Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its holdings in shares of BioNTech by 412.3% in the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock valued at $4,726,000 after purchasing an additional 33,375 shares in the last quarter. Mirabaud & Cie SA purchased a new stake in BioNTech in the 4th quarter valued at approximately $684,000. Bank of New York Mellon Corp grew its holdings in BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after buying an additional 150 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in BioNTech during the fourth quarter worth $1,118,000. Finally, Van ECK Associates Corp raised its holdings in shares of BioNTech by 25.1% in the fourth quarter. Van ECK Associates Corp now owns 118,418 shares of the company's stock worth $13,493,000 after acquiring an additional 23,733 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
